The global antifungal drugs market is projected to develop from $12567 million in 2016 to $17428 million by 2025. Increasing awareness of the various fungal infections amid people is the prime factor up surging the antifungal drugs market globally. The market is anticipated to grow with 3.70% of CAGR throughout the forecasting period.
The antifungal drugs market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal drugs market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines, and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis, and others. The antifungal drugs market by application is segregated into topical antifungal drugs and oral drugs. The antifungal drugs market on the basis of geography is segmented into Asia-Pacific, Europe, Rest of the World and North America.
Lack of hygiene, healthcare policies and programs by the government, and advancement of drug resistance are the major drivers developing the antifungal drugs market.
North America antifungal drugs market possesses the colossal market share in the global antifungal drugs market in 2016. A large number of people suffering from fungal infection and advancement in antifungal biopharmaceuticals in the region is up surging the growth of the antifungal market. The Asia-Pacific region is projected to be the fastest-growing region for the global antifungal drugs market. The Europe antifungal drugs market is estimated to grow during the forecast period.
The leading market players for Antifungal drugs market are Vertex Pharmaceuticals, Teva Pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & Co, Kramer Laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor Pharmaceuticals Inc., Abbott Laboratories, and 3 Baxter.